Analysis of N-acetylgalactosamine-4-sulfatase protein and kinetics in mucopolysaccharidosis type VI patients

D. A. Brooks, P. A G McCourt, G. J. Gibson, L. J. Ashton, M. Shutter, J. J. Hopwood

Research output: Contribution to journalArticlepeer-review

46 Citations (Scopus)

Abstract

A sensitive and specific, monoclonal antibody-based immunoquantification assay has facilitated determination of the N-acetylgalactosamine-4-sulfatase (4-sulfatase) protein content in cultured fibroblasts from normal controls and mucopolysaccharidosis type VI (MPS VI) patients. The assay enabled the quantification of 4-sulfatase protein by using a panel of seven monoclonal antibodies and has shown that fibroblasts from 16 MPS VI patients contained ≤5% of the level determined for normal controls. Fibroblasts from the most severely affected patients contained the lowest levels of 4-sulfatase protein, usually with few epitopes detected, while fibroblasts from mildly affected patients had higher levels of 4-sulfatase protein, with all seven epitopes detected. The pattern of epitope expression is proposed to reflect the conformational changes in the 4-sulfatase protein that arise from different mutations in the 4-sulfatase gene. Immunoquantification in combination with a specific and highly sensitive 4-sulfated trisaccharide-based assay of enzyme activity in these MPS VI patient fibroblasts enabled the determination of residual 4-sulfatase catalytic efficiency (kcat/Km). The capacity of fibroblasts to degrade substrate (catalytic capacity) was calculated as the product of 4-sulfatase catalytic efficiency and the content of 4-sulfatase in fibroblasts. One patient, 2357, with no clinical signs of MPS VI but with reduced 4-sulfatase activity and protein (both 5% of normal) and dermatansulfaturia, had 5% of normal catalytic capacity. The other 15 MPS VI patient fibroblasts had 0%-1.4% of the catalytic capacity of fibroblasts from normal controls and were representative of the spectrum of MPS VI clinical phenotypes, from severe to mild. It is proposed that an enzyme-replacement therapy achieving a correction of >5% of normal catalytic capacity is required to avoid the onset of MPS VI clinical phenotype. Moreover, it is suggested that the restored catalytic capacity must be correctly localized within the lysosomal compartment to enable effective treatment of MPS VI.

Original languageEnglish
Pages (from-to)710-719
Number of pages10
JournalAmerican Journal of Human Genetics
Volume48
Issue number4
Publication statusPublished or Issued - Apr 1991
Externally publishedYes

ASJC Scopus subject areas

  • Genetics

Cite this